Elizabeth Garrett-Mayer

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint Methods for evaluating the performance of diagnostic tests in the absence of a gold standard: a latent class model approach
    Elizabeth S Garrett
    Johns Hopkins University School of Medicine, Division of Biostatistics, Oncology Center, Baltimore, MD 21205, USA
    Stat Med 21:1289-307. 2002
  2. ncbi request reprint The continual reassessment method for dose-finding studies: a tutorial
    Elizabeth Garrett-Mayer
    Division of Oncology Biostatistics, Johns Hopkins University, Baltimore, MD, USA
    Clin Trials 3:57-71. 2006
  3. pmc Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer
    Michelle A Rudek
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB1 1M52, Baltimore, MD 21231, USA
    Breast Cancer Res Treat 139:135-43. 2013
  4. pmc Incorporating scientific knowledge into phenotype development: penalized latent class regression
    Jeannie Marie S Leoutsakos
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, U S A
    Stat Med 30:784-98. 2011
  5. pmc Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole
    Tatiana M Prowell
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer Prev Res (Phila) 4:1993-2001. 2011
  6. ncbi request reprint Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study
    Kala Visvanathan
    Kala Visvanathan, Johns Hopkins University School of Medicine and Bloomberg School of Public Health MaryJo S Fackler, Zhe Zhang, Zoila A Lopez Bujanda, Stacie C Jeter, Lori J Sokoll, Leslie M Cope, Christopher B Umbricht, David M Euhus, Saraswati Sukumar, and Antonio C Wolff, Johns Hopkins University School of Medicine, Baltimore, MD Elizabeth Garrett Mayer, Medical University of South Carolina, Charleston, SC Andres Forero, University of Alabama at Birmingham, Birmingham, AL Anna M Storniolo, Indiana University, Bloomington, IN Rita Nanda, University of Chicago, Chicago, IL Nancy U Lin, Dana Farber Cancer Institute, Boston, MA Lisa A Carey, University of North Carolina, Chapel Hill, NC and James N Ingle, Mayo Clinic, Rochester, MN
    J Clin Oncol . 2016
  7. pmc Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
    Judith E Karp
    Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland 21231 1000, USA
    Haematologica 97:1736-42. 2012
  8. pmc Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors
    Antonio Jimeno
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    J Clin Oncol 26:4172-9. 2008
  9. pmc Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer
    Roisin M Connolly
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1 189, Baltimore, MD 21231 1000, USA
    Breast Cancer Res Treat 127:153-62. 2011
  10. ncbi request reprint Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus
    Aimee R Kreimer
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21231, USA
    J Infect Dis 189:686-98. 2004

Collaborators

Detail Information

Publications15

  1. ncbi request reprint Methods for evaluating the performance of diagnostic tests in the absence of a gold standard: a latent class model approach
    Elizabeth S Garrett
    Johns Hopkins University School of Medicine, Division of Biostatistics, Oncology Center, Baltimore, MD 21205, USA
    Stat Med 21:1289-307. 2002
    ..These methods are applied to diagnostic criteria for depression using Baltimore's Epidemiologic Catchment Area Study Wave 3 data...
  2. ncbi request reprint The continual reassessment method for dose-finding studies: a tutorial
    Elizabeth Garrett-Mayer
    Division of Oncology Biostatistics, Johns Hopkins University, Baltimore, MD, USA
    Clin Trials 3:57-71. 2006
    ..This paper presents the original CRM, and then some of its modified versions. It also explains the specifications that define a CRM design, along with simulated examples of CRMs and standard designs, for illustration...
  3. pmc Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer
    Michelle A Rudek
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB1 1M52, Baltimore, MD 21231, USA
    Breast Cancer Res Treat 139:135-43. 2013
    ..BSA was not the main source of pharmacokinetic variability. Fixed-dose capecitabine is feasible, and simplifies dosing...
  4. pmc Incorporating scientific knowledge into phenotype development: penalized latent class regression
    Jeannie Marie S Leoutsakos
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, U S A
    Stat Med 30:784-98. 2011
    ..Investigation of novel penalty functions may prove fruitful in further refining psychiatric phenotypes...
  5. pmc Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole
    Tatiana M Prowell
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer Prev Res (Phila) 4:1993-2001. 2011
    ....
  6. ncbi request reprint Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study
    Kala Visvanathan
    Kala Visvanathan, Johns Hopkins University School of Medicine and Bloomberg School of Public Health MaryJo S Fackler, Zhe Zhang, Zoila A Lopez Bujanda, Stacie C Jeter, Lori J Sokoll, Leslie M Cope, Christopher B Umbricht, David M Euhus, Saraswati Sukumar, and Antonio C Wolff, Johns Hopkins University School of Medicine, Baltimore, MD Elizabeth Garrett Mayer, Medical University of South Carolina, Charleston, SC Andres Forero, University of Alabama at Birmingham, Birmingham, AL Anna M Storniolo, Indiana University, Bloomington, IN Rita Nanda, University of Chicago, Chicago, IL Nancy U Lin, Dana Farber Cancer Institute, Boston, MA Lisa A Carey, University of North Carolina, Chapel Hill, NC and James N Ingle, Mayo Clinic, Rochester, MN
    J Clin Oncol . 2016
    ..004). Conclusion Methylation of this gene panel is a strong predictor of survival outcomes in MBC and may have clinical usefulness in risk stratification and disease monitoring...
  7. pmc Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
    Judith E Karp
    Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland 21231 1000, USA
    Haematologica 97:1736-42. 2012
    ..6 months...
  8. pmc Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors
    Antonio Jimeno
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    J Clin Oncol 26:4172-9. 2008
    ..We conducted a dose selection study with daily rapamycin (sirolimus) in patients with solid tumors employing a modified continuous reassessment method (mCRM) using real-time pharmacodynamic data as primary dose-estimation parameter...
  9. pmc Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer
    Roisin M Connolly
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1 189, Baltimore, MD 21231 1000, USA
    Breast Cancer Res Treat 127:153-62. 2011
    ..However, these unexpected pharmacokinetic findings support further investigation of mechanisms underlying docetaxel elimination pathways...
  10. ncbi request reprint Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus
    Aimee R Kreimer
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21231, USA
    J Infect Dis 189:686-98. 2004
    ..8; 95% confidence interval, 3.1-52.7) among HIV-seropositive individuals. HPV type 16, which is present in most HPV-associated tonsillar cancers, was the most prevalent high-risk oral HPV infection...
  11. ncbi request reprint Noise, stress, and annoyance in a pediatric intensive care unit
    Wynne E Morrison
    Division of Pediatric Anesthesia and Critical Care, Johns Hopkins School of Medicine, Baltimore, MD, USA
    Crit Care Med 31:113-9. 2003
    ..To measure and describe hospital noise and determine whether noise can be correlated with nursing stress measured by questionnaire, salivary amylase, and heart rate...
  12. pmc Symptoms, supportive care needs, and function in cancer patients: how are they related?
    Claire F Snyder
    Johns Hopkins School of Medicine, Baltimore, MD, USA
    Qual Life Res 17:665-77. 2008
    ..To explore the associations among symptoms, supportive care needs, and function...
  13. doi request reprint Concordance of cancer patients' function, symptoms, and supportive care needs
    Claire F Snyder
    Johns Hopkins School of Medicine, 624 N Broadway, Room 657, Baltimore, MD 21205, USA
    Qual Life Res 18:991-8. 2009
    ..Although patients' function, symptoms, and supportive care needs are obviously related, a better understanding of these relationships could improve patient management...
  14. pmc A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease
    Simon A Williams
    Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Natl Cancer Inst 99:376-85. 2007
    ..Prostate-specific antigen (PSA) is a serine protease that is secreted at high levels by the normal and diseased prostate. Therapies that are activated by PSA may prove effective in treating prostatic malignancies...
  15. pmc Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma
    David M Loeb
    Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Cancer 115:2514-22. 2009
    ..The purpose of the current study was to determine the maximally tolerated dose of (153)Sm-EDTMP that permits hematopoietic recovery within 6 weeks...